Register Login

IKENA ONCOLOGY, INC. (IMA)

SymbolIMA
NameIKENA ONCOLOGY, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
Address645 SUMMER STREET,SUITE 101, BOSTON, Massachusetts, 02210, United States
Telephone+1 857 273-8343
Fax—
Email—
Websitehttps://www.ikenaoncology.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001835579
Description

Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients.

Additional info from NASDAQ:
ImageneBio is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. Imagenes purpose is to globally develop new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life.

Additional info from NASDAQ:
Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients.

2026-06-18 22:45

Wang Jonathan Jian 🟢 acquired 15.6K shares (1 derivative) of ImageneBio, Inc. (IMA) at $5.45 Transaction Date: Jun 16, 2026 | Filing ID: 000002

Read more
2026-06-18 22:45

Stampacchia Otello 🟢 acquired 15.6K shares (1 derivative) of ImageneBio, Inc. (IMA) at $5.45 Transaction Date: Jun 16, 2026 | Filing ID: 000002

Read more
2026-06-18 22:45

SLATTERY JOSEPH P 🟢 acquired 15.6K shares (1 derivative) of ImageneBio, Inc. (IMA) at $5.45 Transaction Date: Jun 16, 2026 | Filing ID: 000004

Read more
2026-06-18 22:45

Bonita David P 🟢 acquired 15.6K shares (1 derivative) of ImageneBio, Inc. (IMA) at $5.45 Transaction Date: Jun 16, 2026 | Filing ID: 000005

Read more
2026-06-17 20:05

(99% Neutral) IKENA ONCOLOGY, INC. (IMA) Announces Executive Changes

Read more
2026-06-17 17:10

New Form 424B3 - ImageneBio, Inc. <b>Filed:</b> 2026-06-17 <b>AccNo:</b> 0001193125-26-274147 <b>Size:</b> 209 KB

Read more
2026-05-27 20:30

ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York

Read more
2026-05-15 17:17

New Form SCHEDULE 13G/A - ImageneBio, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000921895-26-001396 <b>Size:</b> 23 KB

Read more
2026-05-14 17:17

New Form SCHEDULE 13G/A - ImageneBio, Inc. <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 0001140361-26-021307 <b>Size:</b> 7 KB

Read more
2026-05-07 20:12

(10% Negative) IKENA ONCOLOGY, INC. (IMA) Reports Q2 2026 Financial Results

Read more